What this article helps you consider
- Define the measurement before choosing the instrument
- Build understanding during development
- Match validation to the intended use
Define the measurement before choosing the instrument
Begin with the quality attribute and the decision the result must support. An identity test, an assay and a trace impurity determination have different performance needs. State the analyte, matrix, reportable range and the level of uncertainty that is acceptable for the intended decision. An analytical target profile can capture these requirements without committing prematurely to a particular technology.
Q14 describes the analytical target profile and explains that its formal documentation and submission are optional. It should not be presented as a mandatory standalone document for every method. The practical benefit is the discipline of linking method capability to the measurement need. R05
Build understanding during development
Development should examine the variables likely to affect the reported result. For chromatography these may include extraction, pH, stationary phase, gradient delivery, temperature and detection. Sample preparation deserves particular attention because a precise instrument cannot correct incomplete extraction or analyte loss before injection.
Use prior knowledge and risk assessment to prioritise experiments. A multifactor study can be useful where interactions are likely, while a simpler investigation may adequately resolve a narrow question. Q14 accommodates different development approaches; it does not require every procedure to use design of experiments or to establish a formal design space.
Match validation to the intended use
Q2(R2) relates performance characteristics to the type of analytical measurement. The validation plan should justify the selected studies, their design and their acceptance criteria. A quantitative impurity method operating near its lower range needs different evidence from a principal-component assay. The plan should reflect how routine reportable results will actually be generated. R04
Avoid treating a familiar correlation coefficient or precision threshold as a universal regulatory requirement. A high correlation coefficient can coexist with meaningful bias at the bottom of a calibration range. Accuracy and precision must be examined at concentrations relevant to the decision, with suitable consideration of matrix and preparation effects.
Design controls that protect the result
System suitability should detect failures relevant to the procedure, such as inadequate separation of a critical pair. It cannot demonstrate that every sample was weighed, extracted or diluted correctly. Add appropriate preparation controls, solution-stability limits and reference-standard management where their contribution is important.
Consider a hypothetical impurity method with an intended reporting threshold of 0.05%. A convincing development package would show that a 0.05% spike can be recovered and measured in the product matrix, that relevant interferents are controlled and that low-level performance persists across routine operating conditions. The numerical threshold is illustrative, not a standard applicable to all impurities.
Maintain the procedure after validation
Once a procedure is in use, review relevant performance indicators. Recurring integration difficulties, unstable standards or rising invalid-run rates may reveal an emerging problem even when final results remain acceptable. Evaluate changes through the quality system and determine the extent of additional development, validation or transfer work needed.
Stabicon can support a connected development and validation programme in which protocols, experimental evidence and operating controls explain why a procedure is fit for its intended purpose. This gives receiving laboratories and regulatory reviewers a clearer basis for assessing the method.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R04ICH Q2 R2 Validation of Analytical Procedures
Final guideline adopted November 2023. Analytical validation framework.
- R05ICH Q14 Analytical Procedure Development
Final guideline adopted November 2023. Development and lifecycle approaches.
- R06ICH Q10 Pharmaceutical Quality System
Final guideline, 2008. Pharmaceutical quality system and lifecycle management.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






